RxDoctor Payments Data

Katherine Combs

Nurse Practitioner · Saint Louis, MONPI 1013677699

Payments from drug & device makers

$3,022in general payments, 2019–2025

Across 208 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$536
  • Amneal Pharmaceuticals LLC$232
  • Biohaven Pharmaceutical Holding Company Ltd.$180
  • SK Life Science, Inc.$161
  • Sumitomo Pharma America, Inc.$115
  • plus $708 from 16 others

What the payments were for

  • Food & beverage$3,022100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,022 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$26,951
Medicare patients
165
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Glatiramer Acetate13$62,414
QuliptaAtogepant19$22,529
Carbidopa-LevodopaCarbidopa/Levodopa116$3,644
Levetiracetam129$3,290
Entacapone12$3,224
DilantinPhenytoin Sodium Extended13$3,055
Memantine Hcl98$3,030
Carbamazepine ErCarbamazepine14$2,330
Donepezil Hcl193$2,038
Gabapentin101$1,945
Phenytoin Sodium Extended48$1,702
Oxcarbazepine16$1,615
Lacosamide16$1,482
Divalproex Sodium ErDivalproex Sodium24$1,452
Primidone49$1,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$1,090$22,52919 claims
PfizerDilantin, Dilantin$536$3,35324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →